Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P31639
UPID:
SC5A2_HUMAN
Alternative names:
Low affinity sodium-glucose cotransporter; Solute carrier family 5 member 2
Alternative UPACC:
P31639; A2RRD2
Background:
Sodium/glucose cotransporter 2 (SGLT2), also known as solute carrier family 5 member 2, plays a pivotal role in glucose homeostasis. It functions as an electrogenic Na(+)-coupled sugar simporter, facilitating D-glucose reabsorption in the kidney's proximal tubules. This process is essential for maintaining normal glucose levels in the body.
Therapeutic significance:
SGLT2's involvement in renal glucosuria, a condition characterized by abnormal glucose excretion in urine despite normal blood glucose levels, underscores its therapeutic potential. Targeting SGLT2 could lead to innovative treatments for managing glucose levels in patients, offering a promising avenue for diabetes care.